Payment overview · 2025
General Payments
$1,343.86
72 reported records · 20 companies
Healthcare provider profile · identity verified
Sonja Pettus, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JASPER, AL · NPI 1184769424
Verified facts
What the public records show
CMS Open Payments records show Sonja Pettus, M.D. received $1,343.86 in general payments during 2025 across 72 reported records.
Novo Nordisk Inc accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $263.65 | 19.6% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $168.55 | 12.5% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $153.76 | 11.4% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $135.27 | 10.1% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $81.65 | 6.1% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $77.73 | 5.8% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $73.39 | 5.5% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $53.99 | 4.0% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53.61 | 4.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.46 | 3.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.44 | 3.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.98 | 2.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.11 | 2.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.52 | 1.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.48 | 1.6% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.86 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.98 | 1.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.66 | 1.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.41 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.36 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,343.86 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $201.19 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $179.25 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $136.16 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $135.27 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $97.79 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $83.80 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $81.65 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $81.62 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $77.73 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $73.39 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $70.10 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $53.99 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.65 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $53.61 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.46 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.39 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.52 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.98 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.11 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 116 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 128 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 90 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
90 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
128 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 529 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 521 | 140 |
| Losartan Potassium | Losartan Potassium | 492 | 124 |
| Gabapentin | Gabapentin | 425 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 405 | 114 |
| Montelukast Sodium | Montelukast Sodium | 393 | 110 |
| Omeprazole | Omeprazole | 380 | 112 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 374 | 75 |
| Famotidine | Famotidine | 326 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 325 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 316 | 77 |
| Tramadol Hcl | Tramadol Hcl | 298 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 297 | 83 |
| Lisinopril | Lisinopril | 288 | 80 |
| Potassium Chloride | Potassium Chloride | 278 | 91 |
| Alprazolam | Alprazolam | 277 | 39 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 256 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 223 | 58 |
| Furosemide | Furosemide | 217 | 74 |
| Metformin Hcl | Metformin Hcl | 212 | 60 |
| Buspirone Hcl | Buspirone Hcl | 210 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 210 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 206 | 64 |
| Meloxicam | Meloxicam | 206 | 64 |
| Lorazepam | Lorazepam | 201 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 200 | 63 |
| Pravastatin Sodium | Pravastatin Sodium | 198 | 52 |
| Sertraline Hcl | Sertraline Hcl | 193 | 52 |
| Trazodone Hcl | Trazodone Hcl | 186 | 49 |
| Alendronate Sodium | Alendronate Sodium | 176 | 60 |
| Bupropion Xl | Bupropion Hcl | 159 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 42 |
| Glipizide | Glipizide | 150 | 37 |
| Simvastatin | Simvastatin | 146 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 30 |
| Ozempic | Semaglutide | 128 | 21 |
| Carvedilol | Carvedilol | 124 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 121 | 38 |
| Eliquis | Apixaban | 116 | 22 |
| Fluconazole | Fluconazole | 107 | 65 |
| Allopurinol | Allopurinol | 99 | 23 |
| Azithromycin | Azithromycin | 99 | 82 |
| Methylprednisolone | Methylprednisolone | 98 | 80 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 28 |
| Spironolactone | Spironolactone | 92 | 28 |
| Clonazepam | Clonazepam | 91 | 15 |
| Donepezil Hcl | Donepezil Hcl | 91 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 91 | 24 |
| Ibuprofen | Ibuprofen | 91 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 16 |
| Estradiol | Estradiol | 88 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 88 | 30 |
| Xarelto | Rivaroxaban | 84 | 16 |
| Pregabalin | Pregabalin | 83 | 13 |
| Januvia | Sitagliptin Phosphate | 82 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 76 | 60 |
| Baclofen | Baclofen | 74 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 17 |
| Atenolol | Atenolol | 67 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 61 | 11 |
| Nystatin | Nystatin | 60 | 36 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 31 |
| Celecoxib | Celecoxib | 57 | 21 |
| Mirtazapine | Mirtazapine | 57 | 14 |
| Temazepam | Temazepam | 56 | suppressed |
| Irbesartan | Irbesartan | 55 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 45 |
| Methocarbamol | Methocarbamol | 53 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 33 |
| Finasteride | Finasteride | 50 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 50 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 11 |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Naproxen | Naproxen | 46 | 17 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Linzess | Linaclotide | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 11 |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Glimepiride | Glimepiride | 43 | 11 |
| Clonidine Hcl | Clonidine Hcl | 42 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 14 |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 41 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Prednisone | Prednisone | 40 | 16 |
| Amoxicillin | Amoxicillin | 39 | 31 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Lactulose | Lactulose | 38 | 12 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Mupirocin | Mupirocin | 34 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 27 |
| Ezetimibe | Ezetimibe | 33 | 12 |
| Glipizide Er | Glipizide | 33 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 33 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 23 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Cimetidine | Cimetidine | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Metronidazole | Metronidazole | 14 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
| Yuvafem | Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,343.86 · 72 records | Novo Nordisk Inc | ACCRUFER, AIRSUPRA, Auvelity, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, General - Pain Management, IBSRELA, JASCAYD, Kerendia, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, OFEV, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error